Financial Data and Key Metrics Changes - The company reported third quarter revenues of $50.2 million, representing an 11% growth over the third quarter of 2024 and a 49% improvement in adjusted EBITDA compared to the prior year [4][17] - Gross margin decreased to 79.1% in Q3 2025 from 80.1% in Q3 2024 [17] - The net loss for the third quarter was $16.3 million, or $0.26 per share, which is a 6% increase in net loss compared to $15.4 million, or $0.25 per share, in Q3 2024 [18] - Year-to-date net loss decreased by 10% to $49.6 million compared to $55.2 million for the same period in 2024 [18] - Total liquidity as of September 30, 2025, was $80.6 million, down from $90.7 million at the end of Q2 [19] Business Line Data and Key Metrics Changes - The company has expanded its product portfolio to include three new bunion correction systems, aiming to address nearly 100% of surgeon preferences for bunion correction [5][6] - Case volume growth was mid-single digits compared to the prior year, but below original expectations, largely driven by new bunion systems with lower average selling prices (ASPs) [10] - Sales to a limited number of stocking distributors contributed approximately $6 million in the third quarter, which is not expected to recur at the same levels in future quarters [12] Market Data and Key Metrics Changes - A survey indicated that surgeon customers reported a 7% decrease in bunion surgical volumes year-to-date through October compared to the same period last year [11] - Broader economic conditions and softer consumer sentiment have led to deferrals of elective bunion procedures, impacting case volumes [8][11] Company Strategy and Development Direction - The company is transitioning from a single technology focus to a comprehensive bunion solutions provider, with plans to capture market share in minimally invasive osteotomies and MTP fusion markets [5][9] - The strategy includes enhancing the sales team's capabilities and expanding the product portfolio to drive market share gains and improve profitability [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in the current growth trajectory and revised the full-year revenue outlook to $211 million-$213 million, reflecting only 1%-2% growth compared to 2024 [8][20] - The company plans to continue focusing on training existing customers and onboarding new surgeons to drive adoption of new products [13][22] Other Important Information - The company is taking actions to control costs and improve profitability, with a focus on reducing cash burn in 2026 [16][20] - The company has appointed a new Chief Commercial Officer and expanded its sales team to enhance market presence [6] Q&A Session Summary Question: Can you talk about the softness in the core Lapiplasty business? - Management acknowledged a trend towards minimally invasive osteotomies but emphasized the importance of Lapiplasty for significant bunion deformities, stating efforts to capture market share in this area [24][25] Question: What does the guidance imply for Q4 and 2026? - Management refrained from providing specific guidance for 2026 but expressed optimism about case volume growth and the reception of new products [26][27] Question: Has there been an acceleration in the shift away from Lapiplasty? - Management confirmed a trend towards minimally invasive procedures but highlighted ongoing efforts to capture market share with new technologies [30][31] Question: How will the company recoup deferred procedures next year? - Management indicated that improved consumer sentiment and enhanced engagement with new products would help capture a larger share of patients returning for surgery [38]

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts, Inc. made false statements regarding the impact of competition on the demand for its primary product, the 3D bunion correction system, "Lapiplasty" [2]. - It is alleged that due to competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that competition negatively impacted the demand for the Lapiplasty system, leading to a decline in Treace Medical's revenue [3]. - The company needed to accelerate plans for an alternative product to osteotomy due to these challenges [3]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 10, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical Concepts concealed the impact of competition on the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [2] - As a result of competitive pressures, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Defendants allegedly made materially misleading positive statements regarding the company's business, operations, and future prospects [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Financial Performance - Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - Following this announcement, Treace Medical's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competitive pressure, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [3]. - The defendants' positive statements about the company's business and prospects were allegedly misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline set for June 10, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from May 8, 2023, to May 7, 2024 [1] Group 1: Allegations and Impact - The complaint alleges that competition negatively affected the demand and utilization of Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty" [1] - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1] - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of TMCI during the specified class period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - Participation in the case incurs no cost or obligation for the shareholders [2] Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud [2]. - Investors who purchased Treace Medical securities during the Class Period have until June 10, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance cut, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that Treace Medical's primary product, the 3D bunion correction system "Lapiplasty," faced competition that negatively impacted demand and utilization [3]. - The company reportedly experienced a revenue decline and needed to expedite plans for an alternative product to osteotomy [3]. - Defendants are accused of making materially misleading statements about the company's business and prospects [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 10, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information affecting the company's stock value [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants are accused of making materially misleading statements about the company's business operations and future prospects, lacking a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case does not incur any cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of the company's stock [3].